The Distribution Oligopoly — McKesson, Cencora, Cardinal
~90% of US prescription pharmaceuticals flow through three companies. Boring, low-margin — but monopoly-like.
US pharmaceutical distribution is a three-firm oligopoly : McKesson, Cencora (formerly AmerisourceBergen), and Cardinal Health collectively handle ~90% of US prescription pharmaceuticals. Low single-digit margins, very high turnover, hard to disrupt. Specialty pharma distribution (oncology, biologics, GLP-1s) is the higher-margin growth segment. Cold-chain logistics for biologics is increasingly important — even more so for GLP-1 pens that need temperature-controlled distribution.
No realistic fourth entrant. Logistics scale economies make the moat unbreakable for new entrants. Group classification appropriate.
2 names on the watchlist
~90% of US prescription pharma distribution between them. Group classification.
The three giants of US pharma distribution. ~90% of prescriptions flow through these three companies . Low margin, high turnover, monopoly-like. Specialty distribution (oncology, biologics, GLP-1 cold chain) is the higher-margin growth angle. Lower-beta sector exposure that quietly compounds.
Reference only — fill-finish CDMO acquired by Novo Holdings at $63.50, $16.5B EV.
Reference only. Catalent was acquired by Novo Holdings December 2024 at $63.50/share, $16.5B enterprise value. Three fill-finish sites were sold directly to Novo Nordisk for GLP-1 production. No longer publicly investable — included to flag that GLP-1 fill-finish capacity has been partially internalized by Novo.
- Fortune Business Insights, Precedence Research · 2025–2026